Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil (STARSHINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01955161
Recruitment Status : Completed
First Posted : October 7, 2013
Results First Posted : September 19, 2017
Last Update Posted : September 19, 2017
Sponsor:
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
H. Lundbeck A/S

Brief Summary:
To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Placebo Drug: Idalopirdine Phase 3

Detailed Description:
The study consisted of a screening period (up to 2-week period from screening to randomization), a 24-week double-blind treatment period with placebo or idalopirdine 30 mg/day or 60 mg/day as adjunctive therapy to donepezil 10 mg/day, and a 4-week safety follow-up period following study completion or withdrawal from treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 933 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
Study Start Date : October 2013
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016


Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo adjunct to 10 mg Donepezil
Drug: Placebo
Once daily, matching placebo capsules, orally

Experimental: Idalopirdine 30 mg
Idalopirdine adjunct to 10 mg Donepezil
Drug: Idalopirdine
Once daily, encapsulated tablets, orally

Experimental: Idalopirdine 60 mg
Idalopirdine adjunct to 10 mg Donepezil
Drug: Idalopirdine
Once daily, encapsulated tablets, orally




Primary Outcome Measures :
  1. Change in Cognition [ Time Frame: Baseline to Week 24 ]

    Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score.

    The Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog) is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment).



Secondary Outcome Measures :
  1. Change in Daily Functioning [ Time Frame: Baseline to Week 24 ]

    Change from baseline to Week 24 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score.

    The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability).


  2. Change in Global Impression [ Time Frame: Baseline to Week 24 ]

    Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 24.

    The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening).


  3. Change in Behavioural Disturbance [ Time Frame: Baseline to Week 24 ]

    Change from baseline to Week 24 in Neuropsychiatric Inventory (NPI) total score.

    The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome).


  4. Change in Individual Behavioural Disturbance Items [ Time Frame: Baseline to Week 24 ]

    Change in single NPI item scores at Week 24.

    The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). Total score for each single NPI item ranges from 0-12 (frequency multiplied by severity), where higher scores represent worse outcome.


  5. Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline [ Time Frame: Baseline to Week 24 ]

    Change from baseline to Week 24 in NPI anxiety item score in patients with an NPI anxiety item score of at least 2 at baseline

    The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total score for the NPI anxiety item ranges from 0-12 (frequency multiplied by severity), where a higher score represents a worse outcome.


  6. Clinical Improvement [ Time Frame: Week 24 ]
    Clinical response at Week 24 (based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog below or equal to -4, change in ADCS-ADL23 at least 0, and ADCS-CGIC below or equal to 4])

  7. Clinical Worsening [ Time Frame: Week 24 ]
    Clinical worsening at Week 24 (Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog above or equal to 4, change in ADCS-ADL23 below 0, and ADCS-CGIC above 4])

  8. Change in Cognitive Aspects of Mental Function [ Time Frame: Baseline to Week 24 ]
    Change from baseline to Week 24 in Mini Mental State Examination (MMSE). The Mini Mental State Examination (MMSE) is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit).

  9. Change in Health-related Quality of Life (EQ-5D) Utility Score [ Time Frame: Baseline to Week 24 ]

    Change from baseline to Week 24 in EuroQol 5-dimensional (EQ-5D) utility score

    The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). Each descriptive item is rated on a 3-point index ranging from 1 (no problems) to 3 (extreme problems) that is used for calculating a single summary index (from 0 to 1). A higher EQ-5D score indicates a worse outcome.


  10. Change in Health-related Quality of Life (EQ-5D VAS) [ Time Frame: Baseline to Week 24 ]

    Change from baseline to Week 24 in EQ-5D Visual Analogue Scale (EQ-5D VAS).

    The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient has a knowledgeable and reliable caregiver.
  • The patient is an outpatient.
  • The patient has probable AD.
  • The patient has mild to moderate AD.
  • Stable treatment with donepezil.
  • The patient, if a woman, must have had her last natural menstruation ≥24 months prior to baseline, OR be surgically sterile.
  • The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit.

Exclusion Criteria:

  • The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD.
  • The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD.
  • The patient has evidence of clinically significant disease.
  • The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
  • The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.

Other inclusion and exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01955161


Locations
Hide Hide 137 study locations
Layout table for location information
United States, Alabama
US027
Birmingham, Alabama, United States
United States, Arizona
US012
Phoenix, Arizona, United States
United States, Arkansas
US024
Little Rock, Arkansas, United States
United States, California
US053
Glendale, California, United States
US023
Imperial, California, United States
US015
La Jolla, California, United States
US045
Long Beach, California, United States
US002
Los Angeles, California, United States
US058
San Francisco, California, United States
US018
Santa Ana, California, United States
United States, Colorado
US060
Denver, Colorado, United States
United States, Florida
US042
Boca Raton, Florida, United States
US021
Bradenton, Florida, United States
US050
Brooksville, Florida, United States
US019
Orlando, Florida, United States
US038
Port Charlotte, Florida, United States
US001
West Palm Beach, Florida, United States
United States, Georgia
US020
Atlanta, Georgia, United States
United States, Hawaii
US048
Kailua, Hawaii, United States
United States, Illinois
US030
Chicago, Illinois, United States
US051
Joliet, Illinois, United States
United States, Indiana
US040
Indianapolis, Indiana, United States
United States, Maine
US036
Freeport, Maine, United States
United States, Massachusetts
US032
Newton, Massachusetts, United States
United States, Michigan
US035
Kalamazoo, Michigan, United States
United States, Mississippi
US041
Flowood, Mississippi, United States
United States, Missouri
US054
Saint Louis, Missouri, United States
United States, New Jersey
US046
Princeton, New Jersey, United States
US028
Toms River, New Jersey, United States
US044
Toms River, New Jersey, United States
United States, New York
US049
Albany, New York, United States
US010
Amherst, New York, United States
US014
Manhasset, New York, United States
US008
New York, New York, United States
US029
New York, New York, United States
US056
New York, New York, United States
US037
Orangeburg, New York, United States
US043
Staten Island, New York, United States
United States, Ohio
US007
Centerville, Ohio, United States
US006
Columbus, Ohio, United States
United States, Oklahoma
US052
Edmond, Oklahoma, United States
United States, Oregon
US026
Portland, Oregon, United States
United States, Pennsylvania
US057
Jenkintown, Pennsylvania, United States
United States, Virginia
US047
Arlington, Virginia, United States
United States, Wisconsin
US025
Madison, Wisconsin, United States
US004
Milwaukee, Wisconsin, United States
Argentina
AR002
Buenos Aires, Argentina
AR003
Buenos Aires, Argentina
AR006
Buenos Aires, Argentina
AR007
Buenos Aires, Argentina
AR009
Cordoba, Argentina
AR004
Mar del Plata, Argentina
AR005
Mendoza, Argentina
AR008
Mendoza, Argentina
AR010
Rosario, Argentina
Belgium
BE003
Brugge, Belgium
BE002
Brussels, Belgium
BE004
Bruxelles, Belgium
BE005
Leuven, Belgium
BE001
Roeselare, Belgium
BE006
Thuin, Belgium
Bulgaria
BG005
Plovdiv, Bulgaria
BG001
Sofia, Bulgaria
BG002
Sofia, Bulgaria
BG003
Sofia, Bulgaria
BG004
Sofia, Bulgaria
BG006
Sofia, Bulgaria
BG007
Varna, Bulgaria
Canada
CA002
Gatineau, Canada
CA006
London, Canada
CA008
Newmarket, Canada
CA001
Toronto, Canada
CA004
Toronto, Canada
Chile
CL004
Antofagasta, Chile
CL002
Santiago, Chile
CL003
Santiago, Chile
CL005
Santiago, Chile
CL001
Valdivia, Chile
Czechia
CZ006
Brno, Czechia
CZ007
Kutna Hora, Czechia
CZ004
Pardubice, Czechia
CZ003
Praha 10, Czechia
CZ001
Praha 2, Czechia
CZ002
Praha 6, Czechia
CZ005
Rychnov nad Kneznou, Czechia
Denmark
DK003
Aarhus N, Denmark
DK001
Copenhagen, Denmark
DK002
Odense C, Denmark
France
FR006
Besancon Cedex, France
FR008
Limoges Cedex1, France
FR003
Nantes Cedex, France
FR005
Paris cedex 10, France
FR001
Paris, France
FR004
Saint Etienne Cedex 2, France
FR002
Toulouse, France
Germany
DE002
Berlin, Germany
DE006
Ellwangen, Germany
DE010
Günzburg, Germany
DE005
Hannover, Germany
DE007
Heidelberg, Germany
DE009
Munchen, Germany
DE008
Ulm, Germany
DE004
Unterhaching, Germany
Italy
IT004
Ancona, Italy
IT006
Brescia, Italy
IT002
Firenze, Italy
IT005
Genoa, Italy
IT003
Lamezia Terme, Italy
IT001
Milano, Italy
IT007
Palermo, Italy
Poland
PL004
Gliwice, Poland
PL007
Katowice, Poland
PL005
Poznan, Poland
PL006
Sopot, Poland
PL002
Szczecin, Poland
PL003
Warszawa, Poland
PL008
Wroclaw, Poland
Romania
RO002
Bucharest, Romania
RO001
Tirgu Mures, Romania
South Africa
ZA003
Bloemfontein, South Africa
ZA006
Cape Town, South Africa
ZA007
Cape Town, South Africa
ZA004
George, South Africa
ZA005
Port Elizabeth, South Africa
ZA001
Pretoria, South Africa
ZA002
Rosebank, South Africa
Spain
ES002
Alicante, Spain
ES006
Barcelona, Spain
ES005
Manresa, Spain
ES004
Salamanca, Spain
ES001
San Sebastian, Spain
ES003
Santiago de Compostela, Spain
Ukraine
UA008
Dnipropetrovsk, Ukraine
UA006
Kherson,Vil. Stepanivka, Ukraine
UA005
Kyiv, Ukraine
UA007
Kyiv, Ukraine
UA001
Lviv, Ukraine
Sponsors and Collaborators
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@lundbeck.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: H. Lundbeck A/S
ClinicalTrials.gov Identifier: NCT01955161    
Other Study ID Numbers: 14861A
2012-004763-45 ( EudraCT Number )
First Posted: October 7, 2013    Key Record Dates
Results First Posted: September 19, 2017
Last Update Posted: September 19, 2017
Last Verified: August 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents